The US Biopharmaceutical Industry: Perspectives on Future Growth and the Factors that will Drive it
The Pharmaceutical Research and Manufacturers Association has published an industry report — "The US Biopharmaceutical Industry: Perspectives on Future Growth and the Factors that will Drive it".
Key findings of the report include
• As the ability to innovate is increasingly becoming the most important determinant of a nation’s future potential for economic growth and global competitiveness, the biopharmaceutical industry ranks among the most innovative advanced manufacturing industries in the US economy.
• Although the US is currently the world leader in innovative biopharmaceutical R&D and manufacturing, industry executives expressed concern that US leadership cannot be taken for granted.
• The three policy factors identified as most critical for enabling innovation and the resulting economic contributions in biopharmaceutical R&D and manufacturing are (1) coverage and payment policies that support and encourage medical innovation; (2) a well-functioning, science-based regulatory system; and (3) strong IP protections.
• Insights from industry executives informed the development of two potential growth trajectories for the innovative biopharmaceutical industry in the US during the next 10 years, with well over 300,000 retained and newly created jobs at stake between the two scenarios. The industry executives viewed the likelihood of achieving these alternative futures as highly dependent on policy choices made in the US.
To download a free copy of the report, click here.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...